人急性髓系白血病細胞OCI-AML-3

細胞名稱

人急性髓系白血病細胞OCI-AML-3

貨物編碼

BFN60810159

產品規格

T25培養瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研   3類

培養體系

90%DMEM+10%FBS+1%三抗

培養溫度

37℃

二氧化碳濃度

5%

簡介

人急性髓系白血病細胞OCI-AML-3取自57歲男性外周血，懸浮培養。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: LL-100 blood cancer cell line panel.

Doubling time: 28 hours (PubMed=25984343); ~35-40 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep quantitative phosphoproteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Derived from sampling site: Peripheral blood.

基因突變

DNMT3A p.Arg882Cys (c.2644C>T) (PubMed=31160637; DSMZ).

Heterozygous for NPM1 p.Trp288Cysfs*12 (c.860_863dupTCTG) (PubMed=16079892).

HLA信息

/

STR信息

Amelogenin        X

CSF1PO        11,12

D3S1358        16

D5S818        11,13

D7S820        9,10

D8S1179        10,12

D13S317        8,13

D16S539        11,13

D18S51        12,18

D21S11        29,30

FGA        22

Penta D        12,13

Penta E        11,13

TH01        8,10

TPOX        8,11

vWA        17,18

參考文獻

PubMed=30285677; DOI=10.1186/s12885-018-4840-5

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940-940(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)